On April 4, 2024 Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, reported that management will participate in the following investor conferences in April (Press release, Immunocore, APR 4, 2024, View Source [SID1234641781]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Needham Virtual Healthcare Conference
Fireside Chat: Wednesday, April 10, 2024, at 11:00 a.m. EDT
Canaccord Horizons in Oncology
Panel: T-Cell Engagers for Solid Tumors: Monday, April 15, 2024, at 4:00 p.m. EDT
Kempen Life Sciences Conference
1×1 and small group meetings: Tuesday, April 16, 2024

Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.

On April 4, 2024 Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, reported that an abstract reporting preclinical results of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, taking place April 5 – 10, 2024 in San Diego, CA (Press release, Gennao, APR 4, 2024, View Source [SID1234641780]). The poster presentation will showcase exploratory research conducted through Gennao’s ongoing collaboration with the laboratory of Peter M. Glazer, M.D., Ph.D., Chair of the Department of Therapeutic Radiology, Professor of Genetics and Robert E. Hunter Professor of Therapeutic Radiology at the Yale School of Medicine. Specifically, the presentation will demonstrate the potential application of the GMAB platform as an antibody-drug conjugate (ADC) for the treatment of solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the poster presentation are as follows:

Abstract Number: 5801

Title: Targeted delivery of Exatecan to tumors via a novel cell-penetrating, anti-DNA antibody

Session Title: Cancer Treatment: New Technologies

Session Date and Time: Tuesday, April 9, 2024; 1:30 p.m. – 5:00 p.m. Pacific Daylight Time

Presenter: Zaira Ianniello, Ph.D., Yale School of Medicine

Location: Poster Section 22; Poster Number 10

On April 4, 2024 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET (Press release, G1 Therapeutics, APR 4, 2024, View Source [SID1234641779]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the event will be accessible on the Events & Presentations page of View Source

On April 4, 2024 Flamingo Therapeutics ("Flamingo") reported its participation in the following upcoming investor and industry conferences (Press release, Flamingo Therapeutics, APR 4, 2024, View Source;utm_medium=rss&utm_campaign=flamingo-therapeutics-announces-participation-in-the-23rd-annual-needham-virtual-healthcare-conference [SID1234641778]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

23rdAnnual Needham Virtual Healthcare Conference, being held in a virtual format, April 8-11, 2024. Company management will meet with investors in one-on-one meetings during the conference.
BioTrinity London conference, being held April 23-24, 2024, in London, United Kingdom. Stephane van Rooijen, MD, MBA, Chief Executive Officer, will be presenting during the Oncology R&D Spotlight session at 9:15 AM on Tuesday, April 23, 2024.
BioEquity Europe24, being held May 12-14, 2024, in San Sebastian, Spain and online. Company management will meet with potential partners during the conference. Dr. van Rooijen will give a company presentation during the congress.

On April 4, 2024 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that James Dentzer, President and Chief Executive Officer of Curis, will participate at the 23rd Annual Needham Virtual Healthcare Conference being held on April 8 – 11, 2024 (Press release, Curis, APR 4, 2024, View Source [SID1234641776]). Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Format: Company Presentation
Date: Monday, April 8, 2024
Time: 12:45 PM ET
A live webcast and archived replay will be available and can be accessed here or on the Events & Presentations section of Curis’s website.